Molecule UM171 may expand cord blood stem cells | Mosquito genes edited to become resistant to all 4 dengue strains | Nearly 20% of deaths around the world are linked to sepsis, study finds
January 17, 2020
News for the transfusion medicine and cellular therapy community
Researchers have identified a molecule that can be used to expand stem cells from cord blood, according to a study in The Lancet Haematology. The molecule UM171 can help to expand the baseline CD34 cell counts of a unit of cord blood by an average of 35 times, lead author Sandra Cohen said.
The Easy Way to Comply with FDA Guidance With the Platelet PGD Test, the average user can easily test their daily platelet demand in < 1 hour. You only need to test once per dose, and only on the day of transfusion. And, it's the only FDA-cleared rapid test that extends the life of your leukoreduced apheresis platelet inventory to 7 days. Learn More.
Novel biotech mosquitoes have been created by scientists that are resistant to the four strains of dengue, according to findings reported in the journal PLOS Pathogens. The development could boost disease control efforts in countries where dengue is endemic.
The number of sepsis cases around the world in 2017 was estimated at 48.9 million, and the infection killed 11 million people that year, accounting for 19.7% of all global deaths, researchers reported in The Lancet. The study also found that youths younger than 5 accounted for 20.3 million cases of sepsis in 2017 and 2.9 million sepsis-related deaths.
Emendo Biotherapeutics, a startup that says it develops therapies for diseases that are currently untreatable by using the next generation of CRISPR gene editing technology, raised $61 million in its most recent funding round. Japan-based biopharmaceutical firm AnGes led the Series B round.
AABB is pleased to announce it will cohost Transfuse 2020 in collaboration with Mayo Clinic Laboratories. This multidisciplinary conference, to be held May 12-13 in Rochester, Minn., explores the evolution of patient blood management (PBM) to recognize clinical situations where transfusion or factor concentrates are associated with optimizing patient outcomes, as well as identification and effective treatment of anemia. Transfuse 2020 will include an in-depth explanation of the controversies in PBM and how data analytics and diagnostic management teams improve and streamline PBM programs through individualized patient care. Additional information, including registration information and the program agenda, are available online.
